VANCOUVER, B.C. – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical firm growing medicines focusing on ailments with excessive unmet medical want and main the best way within the scientific growth of cannabinol (“CBN”), at present launched particulars of IntegraSynTM, the Company’s new strategy to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a producing system that integrates biosynthesis with different conventional drug manufacturing strategies with the purpose of bettering manufacturing of low-cost, prime quality cannabinoids.As introduced on May 5, 2020, IntegraSynTM is being developed in collaboration with contract growth and manufacturing organizations so as to have the ability to flexibly shift from manufacturing of 1 cannabinoid to a different. The Company lately expanded its program with one among its collaborators to incorporate extra R&D for this manufacturing strategy.
The objectives of IntegraSynTM are to:
- enhance yields past conventional biosynthesis or different commonplace cannabinoid manufacturing strategies;
- cut back prices by minimizing the variety of costly manufacturing steps and use of cost-efficient beginning supplies;
- present manufacturing flexibility in transitioning from one cannabinoid to a different;
- present entry to uncommon cannabinoids which are in any other case impractical / costly to extract from the plant;
- be scalable to fulfill market demand of cannabinoids for pharmaceutical merchandise or different functions; and
- use a sustainable strategy with much less environmental affect than the plant-grow-harvest-extract-purify strategies.
IntegraSynTM is an built-in course of that begins with a bacterial-based fermentation step producing a proprietary, excessive effectivity enzyme in bulk and at low price. On an as-needed foundation, this enzyme is mixed with subtle but cost-efficient substrates in a biotransformation vessel, resulting in cannabinoid meeting. Industry commonplace purification processes and gear are used to provide a high-purity cannabinoid that acts because the energetic pharmaceutial ingredient (“API”), which may very well be inventoried or used as a product for pharmaceutical R&D or for direct commercialization. In addition, the IntegraSynTM course of affords the pliability for this cannabinoid to be additional processed, through both chemical synthesis or through an extra enzyme-driven biotransformation course of adopted by additional purification, leading to a distinct cannabinoid API.
About InMed Pharmaceuticals
InMed Pharmaceuticals is a clinical-stage pharmaceutical firm growing a pipeline of cannabinoid-based medicines, initially centered on the therapeutic advantages of cannabinol (CBN) in ailments with excessive unmet medical want. The Company is devoted to delivering new therapeutic options to sufferers which will profit from cannabinoid-based medicines. For extra info, go to www.inmedpharma.com.
IntegraSynä is InMed’s built-in cannabinoid manufacturing system designed to effectively and economically produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and versatile IntegraSyn manufacturing system integrates a number of commercially confirmed strategies to effectively produce cannabinoids using cost-effective processes.